{"id":"NCT02655224","sponsor":"Takeda","briefTitle":"A Placebo-Controlled, Phase 3 Study of Relugolix (TAK-385) 40 mg in the Treatment of Pain Symptoms Associated With Uterine Fibroids","officialTitle":"A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Oral TAK-385 40 mg in the Treatment of Pain Symptoms Associated With Uterine Fibroids","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-03-26","primaryCompletion":"2017-05-16","completion":"2017-05-19","firstPosted":"2016-01-13","resultsPosted":"2019-03-22","lastUpdate":"2019-03-22"},"enrollment":65,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Uterine Fibroids"],"interventions":[{"type":"DRUG","name":"Relugolix","otherNames":["TAK-385"]},{"type":"DRUG","name":"Relugolix placebo","otherNames":[]}],"arms":[{"label":"Relugolix 40 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of Relugolix (TAK-385) in patients having pain symptoms associated with uterine fibroids.","primaryOutcome":{"measure":"Percentage of Participants With a Maximum NRS Score of 1 or Less During the 28 Days Before the Final Dose of Study Drug","timeFrame":"For 28 days before the final dose of study drug (up to Week 12)","effectByArm":[{"arm":"Relugolix 40 mg","deltaMin":57.6,"sd":null},{"arm":"Placebo","deltaMin":3.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"20 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":11,"countries":["Japan"]},"refs":{"pmids":["31594635"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":33},"commonTop":["Viral upper respiratory tract infection","Metrorrhagia","Hot flush","Menorrhagia","Hyperhidrosis"]}}